Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia
| Autor: | Mei Hong Xiu, Nan Chen, Xiao Ni Guan, Jun Wang, Dong Wang, Jia Hong Liu, Yan Hong Guo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Olanzapine
Oncology medicine.medical_specialty medicine.medical_treatment Weight Gain Benzodiazepines 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Metabolomics Carnitine Antipsychotic Biological Psychiatry First episode business.industry Metabolic disorder medicine.disease 030227 psychiatry Psychiatry and Mental health Drug-naïve Pharmaceutical Preparations Schizophrenia Female medicine.symptom business Weight gain 030217 neurology & neurosurgery Antipsychotic Agents medicine.drug |
| Zdroj: | Journal of Psychiatric Research. 140:409-415 |
| ISSN: | 0022-3956 |
| DOI: | 10.1016/j.jpsychires.2021.06.001 |
| Popis: | Previous studies have demonstrated that patients with schizophrenia (SZ) have greater rate of metabolic disorder as compared with the control population, which likely be the consequence of use of atypical antipsychotics. Olanzapine is a widely used antipsychotic, which increases the weight of SZ patients. However, the underlying mechanism remains poorly understood. Here we report the metabolomics-based understanding of the weight gain induced by olanzapine. 57 first-episode drug-naïve patients (FEDN) were recruited, of whom 27 patients completed a 4-week clinical trial. We then profiled the metabolomes of their plasma with the LC-MS-based nontargeted metabolomics approach at the baseline and after olanzapine monotherapy for 4 weeks. We observed that the plasma of the olanzapine-treated patient had significantly higher lysophosphatidylcholine (LysoPC), lysophosphatidylethanolamine (LysoPE) and lower carnitine as compared with that of the baseline plasma samples. Moreover, regression analyses indicated that the change of LysoPC(14:0) level was an independent contributor to the olanzapine-induced weight gain. Our study suggests that the metabolomics-based approach may facilitate the identification of biomarkers associated with the metabolic disorder causing by antipsychotic in schizophrenia patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect